Angina Drug Approved

APRIL 01, 2006
Susan Farley

The FDA recently approved ranolazine extended-release tablets (Ranexa) for the treatment of angina, making it the first new pharmaceutical option for the treatment of angina in >20 years. According to a statement from the manufacturer, CV Therapeutics Inc, ranolazine prolongs the QT interval and therefore should be used in patients who have not achieved an adequate response with other antianginal drugs. Ranolazine should be used in combination with amlodipine, betablockers, or nitrates. The effect on angina rate or exercise tolerance appeared to be smaller in women than in men. CV Therapeutics expects to have Ranexa available to pharmacies later this spring.

Ms. Farley is a freelance medical writer based in Wakefield, RI.




SHARE THIS SHARE THIS
0
 

AF Risk Increases with More Pregnancies

One study linked multiple pregnancies to an increased risk of developing atrial fibrillation later in life, and another investigated the association between premature delivery and cardiovascular disease.


 

Pharmacy Times Strategic Alliance
 

Pharmacist Education
Clinical features with downloadable PDFs


Next-Generation Pharmacist® Awards


 

SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.